Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease
Frontiers in Cellular and Infection Microbiology · 09.06.2026 · 16
DOI: 10.3389/fcimb.2026.1806927 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 09.06.2026. Verfasst von Ningxin Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Cardiovascular Diseases, Fatty Liver, Metabolic Diseases. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To assess the association between comorbid Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and the risk of developing severe liver disease and cardiovascular disease (CVD) in patients with Chronic Hepatitis B (CHB).
Methods
CHB Patients were continuously recruited from 2012 to 2022 using the electronic medical record system, and divided into CHB-no MASLD and CHB-MASLD groups. Follow-up continued until January 2024, aiming to compare differences of cumulative incidence between the two groups and to analyze associated risk factors.
Results
8,052 patients were included with a median follow-up of 3.9 years. Compared with CHB-no MASLD group, MASLD was independently associated with a 39% lower risk of severe liver disease (adjusted hazard ratio [aHR]=0.61, 95% confidence interval [CI] 0.49-0.76, p < 0.001), with similar effects in cirrhosis (aHR=0.61, 95% CI 0.45-0.82, p= 0.001) and hepatocellular carcinoma (HCC) (aHR=0.57, 95% CI 0.41-0.80, p = 0.001). Stratified analyses indicated the protection effect was more significant in the HBsAg-positive group. Conversely, MASLD was associated with higher CVD risk (aHR=1.16, 95% CI 0.96-1.41, p= 0.130), driven by coronary artery disease (aHR=1.91, 95% CI 1.34-2.74, p < 0.001) and arrhythmia (aHR=1.44, 95% CI 1.00-2.08, p= 0.053). These findings remained consistent after propensity score matching (PSM).
Conclusion
MASLD may reduce the risk of severe liver disease through certain mechanisms, yet it also constitutes a risk factor for CVD, particularly among HBsAg-positive patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
- Health Management Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Information Management, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
- Jiangsu Clinical Medicine Research Institute, Nanjing, China.
- Department of Health Management, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
Zitieren
APA
Zhang, N., Xu, Z., Lin, F., Fan, H., Zhou, D., Zheng, S., Jin, P., Gu, H., Yu, C., & Jiang, L. (2026). Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1806927
Vancouver
Zhang N, Xu Z, Lin F, Fan H, Zhou D, Zheng S, et al. Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1806927
BibTeX
@article{Zhang2026,
author = {Zhang, Ningxin and Xu, Zhongwei and Lin, Fei and Fan, Haozhi and Zhou, Dehong and Zheng, Shiqiu and Jin, Peng and Gu, Huiquan and Yu, Chengxiao and Jiang, Longfeng},
title = {Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1806927}
}
EUVIMED